be prepared for a bad day, again today, tomorrow, monday?
what is going to happen, when the stock market really tanks like 200, 400, or 500 points
GUESSING epacodastat trials coming to a halt
here is the previous statement
1st q estimates for incyte
analysts have a consensus of 265.7m in rev and .26 in earnings
okay looking back we have 3rd q of 2014 of 97.8m, 4th q of 2014 106.00m, 1st q of 2015 115.3.
Being that 1st q is generally the slowest sales of the year, and given we did 182m in 4th q of 2015, sales estimates for 1st q of 2016 are 201m, this comes from using a 9% increase in sales between 4th q of 2014 and 1st q of the 2015 and that there is an extra day in the q this year. Maddi states that contract rev is 58m so, I will agree to that. I will go out on royality of 27m. All total we have revenues of a whopping $286Million
Last q i estimated R&D at 140m, and it came in at 117m. SG&A at 50m and it came in at 52m.
So I see R&D at 128M and SG&A at 57M. and 20M miscellaneous. R&D and SG&A have stock grants included. Costs of 205M.
Now what I do not know , is there costs associated with the stopping of all the ruxolitinib studies, this could be a big number. Will be interesting to see if Jacosa weighs in on this. Also if there was any payments to joint partnerships, Lilly will be charged on 2nd q.
Revenue 286M less costs 205M is earnings of $81M/ share count of 195m is earnings of .415 per share Less
I would like to add, mark to market on agenus shares, based on value on march31. is 4.20 ish , purchased shares roughly 4.70, thus a loss of .50 per share...on almost 12 million shares is 6 million loss.....
I am decreasing sales by 5 million and raising overhead by 10 million
61 million in income 195 m shares gets so .313 income per share
explain to the longs why it is under 70, we are all waiting, you are just like obummer, never answer, always talk about something else.........why, because you are too stupid to say any reasons
See it just goes to show, you have ZERO knowledge or understanding of how the stock markets works. I expected no less, or more from a novice.
just because i say they will have good earnings, does not mean that earnings will not be a bust......what you and the other PUMPERS are missing here, is sediment (feelings of interest in ownership), there was a brief glimmer as Incyte announced the ruxo deal, with lilly, that things will continue to move, and then a complete reversal........as i made mention the other day, watch out when incyte falls through the 50dma........one little pop and you jump all over me, but i am not wrong, share price will continue to crumble.
there is only TWO things moving any bio techs higher, and that is companies that are receiving buyout offers, or FDA approval, nothing else.
if incyte has good earnings and the shares jump from 65 or 68 to 72 is that good? to me no, as it does not get the share price even back to what it was yesterday........i think it could POSSIBLY be sell the news. Well why, you say.......the earnings are coming out on monday versus, thursday, they are delayed 7 business days from usual? If it is not HUGELY POSTIVE news, the shares could tank, as Wall street EXPECTATIONS could be extinguished by a big wet down pour.
i am sure you will have ZERO understanding of what I just wrote.
if you believe in the company so much, why are you not buying shares relentlessly????
m and a
lower short interest
indexed to the naz
indexed in 6 or more bio tech funds
more options per the proxy
buy back of ruxolitinib from lilly
healthcare conference calls
lack of PR
lack of insider stock purchases
retirement of Friedman's team
close ties to novartis
election, though not so much anymore
1.8 BILLION in LOSSES
no real earnings
too much R & D
Thinking you are smarter than 100 other bio tech companies
lack of focus by management team
stock market roll over
signing agreements with other bio tech companies
ownership in agensus shares being under water by millions
Jacosa's rambling, by the way, how did he know
someone associated with the land and building projects is on pregnancy leave???
other than someone who calls on incyte......his BS is worthless
yeah i messed up on the day, but missed my sub 70, by .02 as it hit 70.01 on Thursday. .......lets see if i remember how many times you all have mentioned incyte getting bought out , or 140 by friday......i sure remember that one being a miss by more and .02 cents
that is ok, because i am man enough to say if i am wrong, something the 3 bird brains would never do.........bonk, surprised you came back to the board after your #$%$ slapping and margin calls
looking for sub 70 by monday close, i think though it will trade under it tomorrow for sure, AACR a bust and might as well put ASCO on as a bust also, and incyte will be HUGELY lucky to get a buyout offer above 95IMHO
ok, but gild will be down, tomorrow, so will ibb, in turn incy, so another slaughter fest of a week comes to a close , then it starts again on monday.............maddison says he can not wait for great earnings....well i am the only one on the board to put time behind an estimate. i said they will have a good week. but there is no interest in bio tech, even 3 buyouts today do not help. they were 37 and 50% premiums. so at best incyte is looking at 105, if an offer would come through. cause it will not happen now and incy share price will only go down. as viseslinger says, the employees want to study to death, (keep earning there FAT salaries and mountains of options) instead of getting drugs approved.....nothing but a joke and doubling staff and R and D, how many clinical trials did you just drop?????
And jacosa promised drug results in April on Epacadostat, nothing, so at best more SHELVED projects......
I can name you the best company now to be in in drugs/heathcare/pharma and that is valeant (vrx)....i only wish i had sold more incy...the dog with fleas..........in on vrx in the 27s